DOAC

Antithrombotic Treatment Strategies After Left Atrial Appendage Closure: Current Evidence and Future Perspectives

by
Antithrombotic Treatment Strategies After Left Atrial Appendage Closure: Current Evidence and Future Perspectives

*For medical professionals only The left atrial appendage closure (LAAC) is an effective alternative treatment to long-term oral anticoagulants (OAC) for preventing thromboembolic events related to non-valvular atrial fibrillation (AF). However, antithrombotic therapy is required after LAAC to prevent device-related thrombus (DRT). The optimal antithrombotic strategy post-LAAC remains unclear. LAAC has been in use for … Read more

Exploring Half-Dose DOAC Therapy to Prevent DRT and Reduce Bleeding Risk

by
Exploring Half-Dose DOAC Therapy to Prevent DRT and Reduce Bleeding Risk

On October 13, 2021, a prospective, non-randomized study published in JACC Intervention indicated that after successful left atrial appendage closure (LAAC) using the WATCHMAN device (Boston Scientific), an anticoagulation strategy centered on half-dose direct oral anticoagulants (DOAC) might improve overall surgical outcomes and reduce the occurrence of device-related thrombosis (DRT) compared to standard anticoagulation therapy … Read more